Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Increase of electronegative-LDL-fraction ratio and IDL-cholesterol in chronic kidney disease patients with hemodialysis treatment.

Hirowatari Y, Homma Y, Yoshizawa J, Homma K.

Lipids Health Dis. 2012 Sep 10;11:111. doi: 10.1186/1476-511X-11-111.

2.
3.

Measurement of cholesterol concentrations of major serum lipoprotein classes in haemodialysis patients by anion-exchange chromatography.

Hirowatari Y, Yoshida H, Fueki Y, Ito M, Ogura Y, Sakurai N, Miida T.

Ann Clin Biochem. 2008 Nov;45(Pt 6):571-4. doi: 10.1258/acb.2008.008018. Epub 2008 Sep 9.

PMID:
18782818
4.

Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.

Yiğitoğlu MR, Polat MF, Akçay F, Ari Z, Uyanik BS, Ozilgili HM.

Jpn Heart J. 1997 Jan;38(1):83-9.

PMID:
9186284
5.

Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.

Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H.

Atherosclerosis. 1997 Jun;131(2):229-36.

PMID:
9199276
6.

Utility of non-high-density lipoprotein cholesterol in hemodialyzed patients.

Schreier L, González AI, Elbert A, Berg G, Wikinski R.

Metabolism. 2004 Aug;53(8):1013-5.

PMID:
15281010
7.

Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.

Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H.

Clin Nephrol. 1995 Apr;43(4):268-77.

PMID:
7606882
8.

Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.

Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H.

Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2615-22. Epub 2005 Sep 29.

9.

[Very low density lipoproteins and subclasses of intermediate density lipoproteins in postmenopausal women].

Berg G, Halperín H, Siseles N, Wikinski R.

Medicina (B Aires). 1996;56(5 Pt 1):479-86. Spanish.

PMID:
9239883
10.

The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.

Pennell P, Leclercq B, Delahunty MI, Walters BA.

Clin Nephrol. 2006 Nov;66(5):336-47.

PMID:
17140163
11.

Effects of pancreas transplantation on distribution and composition of plasma lipoproteins.

Föger B, Königsrainer A, Palos G, Ritsch A, Tröbinger G, Menzel HJ, Lechleitner M, Doblinger A, König P, Utermann G, Margreiter R, Patsch JR.

Metabolism. 1996 Jul;45(7):856-61.

PMID:
8692021
12.

Lipoprotein profile in patients who survive a stroke.

Oravec S, Krivosikova Z, Krivosik M, Gruber K, Gruber M, Dukát A, Gavorník P.

Neuro Endocrinol Lett. 2011;32(4):496-501.

PMID:
21876499
14.

Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients.

Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H.

J Am Soc Nephrol. 1998 Jul;9(7):1277-84.

15.

Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients.

Wanner C, Krämer-Guth A, Nauck M, Quaschning T, Pavenstädt H, Schollmeyer P.

Miner Electrolyte Metab. 1996;22(1-3):39-46.

PMID:
8676822
16.

Comparative study between anion-exchange HPLC and homogeneous assay methods in regard to the accuracy of high- and low-density lipoprotein cholesterol measurement.

Kurosawa H, Yoshida H, Yanai H, Ogura Y, Hirowatari Y, Tada N.

Clin Biochem. 2007 Nov;40(16-17):1291-6. Epub 2007 Aug 10.

PMID:
17826753
17.

Effect of diabetes on uremic dyslipidemia.

Kimoto E, Shoji T, Emoto M, Miki T, Tabata T, Okuno Y, Ishimura E, Inaba M, Nishizawa Y.

J Atheroscler Thromb. 2002;9(6):305-13.

18.

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.

Diabetes. 2003 Mar;52(3):803-11.

19.

Atherogenic lipoproteins in end-stage renal disease.

Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S30-3. Review.

PMID:
11576918
20.

Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients.

Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H.

Kidney Int Suppl. 1999 Jul;71:S134-6.

PMID:
10412757

Supplemental Content

Support Center